You and Respert are exactly right, IMO. I can't im
Post# of 149151
So for me the only question is who is the suitor? Madrigal? Their market cap is only 7 billion, so that would involve a licensing deal at best. If it's somebody with deeper pockets and a broader sweep in mind, maybe GSK? They had a GLP-1 agonist (Tanzeum) which they withdrew from the market back in 2017 due to it's being less effective than Ozempic and Mounjaro, maybe this gets them back in that market plus HIV and all the other indications on Ohm's list. Plus, Max Detaillade is still a GSK guy as far as I'm concerned.
Who knows, but big things are in store, it's a great time to be long CYDY.